Adial Pharmaceuticals terminates CMO Dr. Bankole A. Johnson, effective May 17, 2024

ADIAL PHARMACEUTICALS, INC.

Company provided notice to Dr. Johnson on April 10, 2024, terminating consulting agreement.
Termination effective May 17, 2024; Dr. Johnson will no longer serve as Chief Medical Officer.
No successor or replacement Chief Medical Officer announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Bankole A. Johnson

Chief Medical Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2024-05-17
Filed: April 16, 2024, 7:59 PM ET

As a result of the termination of the Consulting Agreement, effective as of May 17, 2024, Dr. Johnson will no longer serve as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Bankole A. Johnson was terminated as Chief Medical Officer at ADIAL PHARMACEUTICALS, INC..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

As a result of the termination of the Consulting Agreement, effective as of May 17, 2024, Dr. Johnson will no longer serve as the Company’s Chief Medical Officer.

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-033471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.